Voxelotor

(Oxbryta®)

Oxbryta®

Drug updated on 11/14/2023

Dosage FormTablet (oral: 500 mg) Tablet for oral suspension (oral; 300 mg)
Drug ClassHemoglobin S polymerization inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.